- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02134964
Phase 1 Safety and PK Study of OLT1177 Capsules
March 5, 2015 updated by: Olatec Therapeutics LLC
A Phase 1, Randomized, Dose Escalation, Single Center, Safety and Pharmacokinetic Study of Single and Multi-Dose, Orally Administered OLT1177 Capsules in Healthy Subjects
This study is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers after administration of single or multiple dose(s) of investigational drug (OLT1177 Caps or Placebo Caps).
A total of 36 subjects will be enrolled across 6 cohorts, and subjects in each cohort will be randomized in a ratio of 5 active to 1 placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
College Station, Texas, United States, 77845
- J&S Studies, Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 to 60 years old, inclusive
- In good health as determined by the Investigator based on subject's medical history, ECG and physical examination at Baseline and safety laboratory tests (chemistry, hematology, coagulation and urinalysis) at Screening
- Normal blood pressure of 130/85 mmHg or lower
- Ability to provide written, informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study
Exclusion Criteria:
Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential who:
- Are or intend to become pregnant (including use of fertility drugs) during the study
- Are nursing
- Are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete. (Acceptable, highly effective forms of contraception are defined as: oral contraception, intrauterine device, systemic [injectable or patch] contraception, double barrier methods, naturally or surgically sterile, strict abstinence or partner has been sterilized. If hormonal-based birth control is being used, subject or subject's sexual partner(s) must be on a stable-dose for ≥ 3 months prior to the Baseline visit and maintained at the same dosing level throughout the study.)
- Use of any drug treatment at the time of the study (with the exception of 81 mg aspirin and prescription oral or systemic contraceptives)
- Taking any prescription medications (other than oral or systemic contraceptives) within 14 days prior to administration of investigational drug or taking any over-the-counter products (including natural food supplements, vitamins, garlic as a supplement) within 14 days prior to administration of investigational drug, except for topical products without systemic absorption
- Use of NSAIDs or other prescription pain medication, more than once or twice a week, especially if taken for chronic or frequently recurring headache
- Active infection within 3 days of the Baseline visit
- History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or antibodies to Hepatitis C Virus (HCV)
- Diagnosed with any form of internal cancer within the past 5 years
- Any other medical conditions, diseases or prior surgeries that in the opinion of the Investigator would impair the subject from safely participating in the trial and/or completing any protocol requirements
- History of anaphylactic reactions to any systemic or topical compounds
- Have donated plasma (500 mL) within 7 days prior to drug administration
- Have donated or lost whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows: 50 mL to 499 mL of whole blood within 30 days, or more than 499 mL of whole blood within 56 days prior to drug administration
- Is a user of any nicotine products (including chewing tobacco, snuff and/or e-cigarettes)
- Is not willing to restrict food or beverage including: alcohol, caffeine, poppy seeds, xanthine derivatives or xanthine-related compounds, energy drinks, natural health products, grapefruit juice, pomelo, Seville orange and marmalade use during the study as specified in Section 7.1.5
- Is lactose intolerant
- Is unable or unwilling to consume products containing bovine byproducts
- Is unable to adhere to or understand the requirements of the protocol
- If continuing on to Part B, subject is unable or unwilling to ingest the full study-provided high-fat breakfast within 30 minutes
- Enrollment in any trial and/or use of any Investigational Drug or device within the immediate 30-day period prior to the Baseline visit
- Enrollment in any study previously sponsored by Olatec Industries LLC, specifically Study OLT1177-01, Study OLT1177-02 or Study OLT1177-03
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OLT1177 Capsules
A total of 5 patients in each cohort will receive OLT1177 Capsules:
|
OLT1177 Capsules are an experimental drug.
|
Placebo Comparator: Placebo Capsules
A total of 1 patient in each cohort will receive Placebo Capsules:
|
Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recording of adverse events
Time Frame: Screening through Day 28 follow-up
|
Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event.
|
Screening through Day 28 follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Laboratory Measurements
Time Frame: Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Blood samples will be drawn and analyzed for: chemistry, hematology, lipids and coagulation.
|
Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Electrocardiogram
Time Frame: Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Electrocardiograms will be captured and analyzed for changes throughout the duration of the study.
|
Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Vital Signs
Time Frame: Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Vital signs (pulse, resting blood pressure, temperature and respirations) will be recorded and analyzed for changes throughout the duration of the study.
|
Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Physical Examination
Time Frame: Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Physical examinations will be conducted to assess changes in subject health throughout the duration of the study.
|
Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Terry M Jones, MD, FAAD, J&S Studies
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2014
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
May 7, 2014
First Submitted That Met QC Criteria
May 7, 2014
First Posted (Estimate)
May 9, 2014
Study Record Updates
Last Update Posted (Estimate)
March 6, 2015
Last Update Submitted That Met QC Criteria
March 5, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OLT1177-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on OLT1177 Capsules
-
Olatec Therapeutics LLCCTI Clinical Trial and Consulting ServicesTerminatedCovid19 | Cytokine Release SyndromeUnited States, Switzerland
-
Olatec Therapeutics LLCCompleted
-
Olatec Therapeutics LLCRadboud University Medical CenterTerminated
-
Olatec Therapeutics LLCCompletedOsteoarthritis of the KneeUnited States
-
Olatec Therapeutics LLCCompletedHealthy VolunteersUnited States
-
Olatec Therapeutics LLCRecruitingArthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout AttackUnited States, Spain, France
-
University Hospital, Basel, SwitzerlandOlatec Therapeutics LLC; State Secretariat for Education Research and Innovation... and other collaboratorsNot yet recruitingDiabetes Mellitus, Type 2Switzerland
-
Olatec Therapeutics LLCCompleted
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark